Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis

  • Cancer Med. 2023 Mar;12(6):6477-6487. doi: 10.1002/cam4.5416.
Qiong Yi  1  2 ,  Canyu Liu  1  3 ,  Yingshan Cui  1  4 ,  Yanguang Yang  2 ,  Yaqi Li  1 ,  Xingwen Fan  1  5  6  7 ,  Kailiang Wu  1  5  6  7
Affiliations
  • 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • 2. Department of Radiation Oncology, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong, China.
  • 3. Department of Radiation Oncology, Suzhou Dushu Lake Hospital, Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University, Suzhou, China.
  • 4. Department of Radiation Oncology, Jinhua Hospital, Zhejiang University School of Medicine, Jinhua Municipal Central Hospital, Zhejiang, China.
  • 5. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • 6. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China.
  • 7. Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
PMID: 37012831 DOI: 10.1002/cam4.5416
Abstract

Purpose: This single-center retrospective clinical study aimed to evaluate the efficacy and feasibility of chemoradiotherapy with paclitaxel Liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC).

Methods: Patients with locally advanced ESCC treated with paclitaxel-liposome-based chemoradiotherapy between 2016 and 2019 were retrospectively analyzed. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis.

Results: Thirty-nine patients with locally advanced ESCC were included in this study. The median follow-up time was 31.5 months. The median OS time was 38.3 (95% confidence interval [CI]: 32.1-45.1) months, and the 1-, 2-, and 3-year OS rates were 84.6%, 64.1%, and 56.2%, respectively. The median PFS time was 32.1 (95% CI: 25.4-39.0) months, and the 1-, 2-, and 3-year PFS rates were 71.8%, 43.6%, and 43.6%, respectively. The most common Grade IV toxicity was neutropenia (30.8%) followed by lymphopenia (20.5%). There were no cases of Grade III/IV radiation pneumonia, and four patients (10.3%) had Grade III/IV esophagitis.

Conclusion: Chemoradiotherapy using paclitaxel Liposome and cisplatin is a well-tolerated and effective treatment regimen for locally advanced ESCC.

Keywords
chemoradiotherapy; esophageal squamous cell carcinoma; paclitaxel liposome.
Products